ITI-9001 enters Phase 1 as Immunomic Therapeutics tests disease-modifying allergy vaccine
See how ITI-9001 could reshape Japanese cedar allergy treatment and what its Phase 1 trial must prove on safety, efficacy and durability.
GlycoNex targets Prolia and Xgeva space as SPD8 meets Phase III equivalence goal
Find out how GlycoNex’s SPD8 Phase III data could intensify denosumab biosimilar competition in osteoporosis and oncology care.
Could BioCardia, Inc.’s integrated platform overcome variability in cardiac regenerative treatments
Discover how BioCardia, Inc.’s Heart3D platform could reduce variability in cardiac cell therapy. Read the full analysis on what this means next.